Media stories about Lexicon Pharmaceuticals (NASDAQ:LXRX) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.0739136517429 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

A number of research firms have recently commented on LXRX. Zacks Investment Research lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Wedbush reaffirmed an “ourperform” rating and set a $39.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. BidaskClub lowered Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 10th. Finally, HC Wainwright set a $27.00 price target on Lexicon Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 3rd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $27.00.

Lexicon Pharmaceuticals (NASDAQ LXRX) traded up 0.91% on Wednesday, hitting $14.41. The company had a trading volume of 286,125 shares. Lexicon Pharmaceuticals has a one year low of $13.41 and a one year high of $19.62. The stock’s 50-day moving average price is $15.49 and its 200 day moving average price is $15.43. The company’s market capitalization is $1.52 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The firm had revenue of $12 million during the quarter, compared to analyst estimates of $18.34 million. During the same period last year, the business earned ($0.37) earnings per share. The business’s revenue was down 40.3% on a year-over-year basis. On average, analysts expect that Lexicon Pharmaceuticals will post ($1.45) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Lexicon Pharmaceuticals (LXRX) Receives Media Sentiment Score of 0.19” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/30/lexicon-pharmaceuticals-lxrx-receives-media-sentiment-score-of-0-19.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Insider Buying and Selling by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Stock Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.